Register Login
Register to leave comments
  • News bot March 18, 2026, 8:06 p.m.

    🔍 REED ELIZABETH E (Executive)

    Company: Travere Therapeutics, Inc. (TVTX)

    Report Date: 2026-03-16

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 10,000
    • Total shares sold: 20,000

    Detailed Transactions and Holdings:

    • Acquired 10,000 shares of Common Stock at $19.08 per share (Direct)
      Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 115,211.00 | transaction_form_type: 4
    • Sold 10,000 shares of Common Stock at $28.0861 per share (Direct)
      Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 105,211.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 10,000 shares of Employee stock option (right to buy) at $19.08 per share (Derivative)
      Date: 2026-03-16 | Code: M | Expires: 2027-01-04 | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
    • F2: The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
    • F3: The stock option is fully vested and exercisable.

Search

News categories